Perrigo Soars on Strong Q4 Revenue Beat and Upbeat Outlook

Perrigo Company plc (PRGO) shares jumped 18.4% in premarket trading on Friday, February 28, 2025, following the consumer healthcare company's fourth-quarter revenue beat and upbeat outlook. The Dublin-based company reported Q4 revenue of $1.29 billion, surpassing the consensus estimate of $1.2 billion. However, adjusted earnings per share (EPS) of $0.93 fell short of the $0.95 analysts were expecting. For the full year 2024, Perrigo reported net sales of $4.37 billion, down 6.1% YoY, and adjusted diluted EPS of $2.57, in line with the midpoint of its previously communicated guidance range.

Perrigo's strong Q4 revenue beat and upbeat outlook have driven investor optimism, as reflected in the sharp stock price jump. The company's focus on stabilizing, streamlining, and strengthening its core businesses has resonated with investors, who are now more confident in Perrigo's long-term growth prospects. Perrigo's strategic initiatives, such as Project Energize and Supply Chain Reinvention, have contributed to a $27 million increase in adjusted operating income in Q4 compared to the prior year period, demonstrating the company's commitment to improving its financial performance and long-term growth prospects.



Perrigo's infant formula net sales grew 17% in Q4 compared to the prior year quarter, driven primarily by market share gains and recovering customer inventory levels. This growth aligns with the company's focus on stabilizing its core businesses and demonstrates its ability to adapt to market trends. Perrigo's upbeat outlook for 2025 suggests that the company is confident in its ability to continue growing and improving its financial performance, further boosting investor confidence.



Perrigo's recent financial performance, particularly its Q4 revenue beat and upbeat outlook, has significantly influenced investors' confidence in the company's long-term growth prospects. The company's strategic initiatives, such as Project Energize and Supply Chain Reinvention, have contributed to this positive sentiment, as reflected in the sharp stock price jump and analysts' optimistic ratings. Perrigo's focus on stabilizing, streamlining, and strengthening its core businesses positions the company to capitalize on market opportunities and mitigate risks in the volatile consumer healthcare sector.

Important note: Investors are reminded to do their due diligence and not rely on the information provided as financial advice. Consider this article as supplementing your required research. Please always apply independent thinking.